Antibodies, convalescent plasma, gene-based vaccines — you may have heard these terms on the evening news, but what do they mean? How might they help in the battle against Covid-19? As the race to develop a vaccine continues, questions remain about effectiveness, testing, and whether people will actually get the vaccine once it’s on the market. Two medical experts involved in the fight explain the science behind developing effective protection. Judith Aberg is Chief of the Division of Infectious Diseases for Mount Sinai Health System. She’s leading Mount Sinai’s Covid-19 treatment guidelines and the hospital’s clinical trials unit. Florian Krammer is a professor of vaccinology at the Icahn School of Medicine at Mount Sinai. Kenneth L. Davis, president and CEO of Mount Sinai Health System, leads the conversation. Davis is a trustee of the Aspen Institute.As a 501(c)(3) nonprofit organization, the Aspen Institute is nonpartisan and does not endorse, support, or oppose political candidates or parties. Further, the views and opinions of our guests and speakers do not necessarily reflect those of the Aspen Institute. aspenideas.org

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related